Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 260

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 8
Chunk 260
---
,012

    62,023

    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
     
    $
    113,218

    $
    101,019

See accompanying notes to the consolidated financial statements.

97

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

    Year Ended December 31,

    2024

    2023

    REVENUES:

    Collaboration revenues
     
    $
    8,149

    $
    7,588

    Royalties, license and other revenues

    1,350

    1,357

    Total revenues

    9,499

    8,945

    OPERATING EXPENSES:

    Cost of sales

    334

    671

    Research and development

    12,472

    15,705

    General and administrative

    18,171

    17,302

    Total operating expenses

    30,977

    33,678

    Loss from operations

    (21,478
    )

    (24,733
    )

    OTHER INCOME (EXPENSES):

    Interest income, net

    1,715

    1,629

    Loss on marketable equity securities, net

    (8
    )

    (176
    )

    Change in fair value of warrant liability

    2,128

    —

    Foreign currency transaction loss, net

    (269
    )

    (544
    )

    Other income (expense), net

    (670
    )

    542

    Total other income (expenses)

    2,896

    1,451

    LOSS BEFORE INCOME TAXES

    (18,582
    )

    (23,282
    )

    Provision for income tax benefit

    —

    1,803

    NET LOSS

    (18,582
    )

    (21,479
    )

    Net (income) loss attributable to noncontrolling interest

    (27
    )

    (7
    )

    NET LOSS ATTRIBUTABLE TO LINEAGE
     
    $
    (18,609
    )
     
    $
    (21,486
    )

    Net loss per common share